SGLT2 versus DPP4 Inhibitors for Type 2 Diabetes: A Meta-analysis
10.11969/j.issn.1673-548X.2017.04.031
- VernacularTitle:恩格列净与DDP4抑制剂治疗2型糖尿病疗效比较的Meta分析
- Author:
Zhepu YANG
;
Huimin BI
- Keywords:
Empagliflozin;
DDP4 inhibitors;
Type 2 diabetes;
Meta-analysis
- From:
Journal of Medical Research
2017;46(4):116-123
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy of empagliflozin and DDP4 inhibitors in the treatment of type 2 diabetes mellitus.Methods With Computer,we retrieval PubMed,Cochrane Library,EMbase,CNKI,CBM and Wanfang database to find all of the randomized controlled trials about the effectiveness and safety of empagliflozin and DDP4 inhibitors in the treatment of type 2 diabetes mellitus.The retrieval time was from the establishment of database to March,2016.References screen were performed manually.Meta-analysis was carried out using RevMan 5.2 software.Results A total of five studies included 1935 cases.The Meta analysis results showed that:HbA1c level (MD =-0.07,95％ CI:-0.13--0.01,P ＜0.05),fasting blood glucose (MD =-16.73,95％ CI:-21.02--12.43,P ＜ 0.01),weight loss level (MD =-2.43 95％ CI:-2.68--2.19,P ＜ 0.01) in the two groups showed statistically significant differences.Empagliflozin group was better than DDP4 inhibitors group in reducing HbA1c level,fasting blood glucose,weight loss level.Safety:hypoglycemia between the two groups were similar (OR =0.86,95％ CI:0.46-1.6,P ＞ 0.05).Empagliflozin group's genital tract infection rate was statistically significant higher than that of DDP4 inhibitors.(OR =2.85,95％ CI:1.71-4.76,P ＜ 0.01).Conclusion Empagliflozin can effectively reduce the fasting blood glucose,HbAIc,and body weight,but increase the incidence of genital infection compare with DDP4 inhibitors.
